Hanmi Pharmaceutical's Next-Gen Immunomodulatory Anti-Cancer Drug Highlights Distinctive Receptor Binding Power
Hanmi Pharmaceutical recently announced a significant advancement in their next-generation immunomodulatory anticancer drug, "LAPS IL-2 Analog (HM16390)," by presenting their preclinical research results at the Society for Immunotherapy of Cancer …